Oslo/Leverkusen – Norwegian radiotherapy specialist Algeta ASA and German drugmaker Bayer have presented new data on their cancer drug alpharadin. The radium-223-chloride pharmaceutical showed an increased overall survival rate compared to placebo (14 months vs. 11.2 months). Experts at the European Multidisciplinary Cancer Conference in Oslo hailed the drug as a “game-changer” for the treatment of prostate cancer, because it is the first to improve bone symptoms and prolong survival. Bayer announced it will seek FDA-approval in the middle of 2012. The advent of Alpha´radin might block efforts by Amgen (Xgeva) and Exelixis (cabozantinib) to advance their respective prostate cancer drugs. “Alpharadin raises the bar for Exelixis. They have to produce overall survival data now,” said Sally Church, a cancer drug consultant with Icarus Consultants.